• Product Name: Measles, Mumps, and Rubella Virus Vaccine, Live
• Tradename: M-M-R II
• Manufacturer: Merck & Co., Inc.
• Vaccine Ontology ID: VO_0000069
• CDC CVX code: 03
• Type: Live, attenuated vaccine
• Status: Licensed
• Location Licensed: USA(License #0002), Canada
• Host Species for Licensed Use: Human
• Allergen: Gelatin, Neomycin, Eggs
• Preparation: The growth medium for rubella is Minimum Essential Medium (MEM) [a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum] containing recombinant human albumin and neomycin. Sorbitol and hydrolyzed gelatin stabilizer are added to the individual virus harvests (FDA: MMR-II).
• Immunization Route: subcutaneous injection
• Storage: 2 to 8°C (36 to 46°F) or colder. Do not freeze.
• Approved Age for Licensed Use: 12 months or older
• Contraindication: Hypersensitivity to any component of the vaccine, a history of anaphylactic or anaphylactoid reactions to neomycin (FDA: MMR-II).
• Description: M-M-R II is a sterile lyophilized preparation of (1) ATTENUVAX* (Measles Virus Vaccine Live), a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; (2) MUMPSVAX* (Mumps Virus Vaccine Live), the Jeryl Lynn** (B level) strain of mumps virus propagated in chick embryo cell culture; and (3) MERUVAX* II (Rubella Virus Vaccine Live), the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts (FDA: MMR-II).

• Product Name: Measles, Mumps, Rubella and Varicella Virus Vaccine Live
• Tradename: ProQuad
• Manufacturer: Merck & Co, Inc.
• Vaccine Ontology ID: VO_0000091
• CDC CVX code: 94
• Type: Live, attenuated vaccine
• Status: Licensed
• Location Licensed: USA (License #0002)
• Host Species for Licensed Use: Human
• Preparation: propagated in WI-38 human diploid lung fibroblasts (FDA: Proquad).
• Immunization Route: Intramuscular injection (i.m.)
• Storage: 2° to 8°C (36° to 46°F) or colder.
• Approved Age for Licensed Use: 12 months to 12 years old
• Contraindication: Vaccine should not be administered to anyone with a known history of anaphylactic reactions to neomycin, or to anyone with a history of hypersensitivity to gelatin or any other component of the vaccine (FDA: Proquad).
• Description: ProQuad is a sterile lyophilized preparation of (1) the components of M-M-R*II (Measles, Mumps and Rubella Virus Vaccine Live): Measles Virus Vaccine Live, a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; Mumps Virus Vaccine Live, the Jeryl Lynn™ (B level) strain of mumps virus propagated in chick embryo cell culture; Rubella Virus Vaccine Live, the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts; and (2) Varicella Virus Vaccine Live (Oka/Merck) refrigerator-stable formulation, the Oka/Merck strain of varicella-zoster virus propagated in MRC-5 cells (FDA: Proquad).

Human Response

• Immune Response: Neutralizing and ELISA antibodies to measles, mumps, and rubella viruses are still detectable in most individuals 11 to 13 years after primary vaccination (FDA: MMR-II).
• Side Effects: Side effects of vaccination are: fever, headache, dizziness, and irritability.
• Efficacy: Many clinical studies have shown the vaccine have a high rate of efficacy protection after vaccination with MMR-II (FDA: MMR-II).

Human Response

• Immune Response: According to clinical trials, there were high levels of antibodies in 99.6% of those vaccinated after a single dose of Proquad (FDA: Proquad).
• Side Effects: Side effects of vaccination include: injection site reactions, fever, irritability and diarrhea.